The U.S. Food and Drug Administration has reviewed new drug stability data and approved a shelf life extension from 12 to 24 months for NAYZILAM® (midazolam) nasal spray, CIV. NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.¹

During my time in the Navy, I developed a strong sense of purpose, service and mission. After fulfilling my service obligation, I was eager to find another career that continued to allow me to do something larger than myself. I found at UCB, a company that makes medicines to help improve the lives of people living with epilepsy, a different type of service: service to patients.

UCB spoke with caregiver, Debbie, about her experience caring for her daughter living with epilepsy and its personal impact on her, as well as the important role of telehealth in epilepsy care. Her story speaks to the challenges many caregivers face when looking after their loved ones and the importance of prioritizing their own mental health. As one of UCB’s Epilepsy Advocates and as a patient advocate for the Epilepsy Foundation, Debbie supports others living with epilepsy and their families throughout their healthcare journey. In these roles, she helps many find access to the right mental health resources, which she says can be a “game changer” for both epilepsy patients and their loved ones.

UCB is excited to exchange ideas at ACR Convergence, Nov. 3-9, 2021. Learn more about our presence at the conference and work in rheumatology from Dr. Jeffrey Stark, Head of Immunology Medical Affairs U.S.

UCB spoke with Tim, who has been living with epilepsy since 1979 while he was on active duty. His story focuses on the challenges that epilepsy brings but also shares how his new, positive outlook on life has changed the way he lives. As a member of UCB’s Epilepsy Advocate program, Tim helps to support other epilepsy patients and has been a resource for others during their journey with epilepsy.

As innovators in the healthcare industry, UCB and The Innovation and Value Initiative (IVI) believe recognizing patient voices in value assessments is important. In our recent Voices on Values series, our Head of U.S. HEOR Strategy, Edward Lee, sat down with Jennifer Bright, Executive Director at IVI to discuss how we can ensure all patient voices are captured in value assessments. Learn more about their conversation.